Impact of Chronic Kidney Disease on Major Bleeding Complications and Mortality in Patients With Indication for Oral Anticoagulation Undergoing Coronary Stenting

被引:15
作者
Manzano-Fernandez, Sergio [2 ]
Marin, Francisco [2 ]
Pastor-Perez, Francisco J. [2 ]
Caro, Cesar [2 ]
Cambronero, Francisco [2 ]
Lacunza, Javier [2 ]
Pinar, Eduardo [2 ]
Pascual-Figal, Domingo A. [2 ]
Valdes, Mariano [2 ]
Lip, Gregory Y. H. [1 ]
机构
[1] City Hosp, Univ Dept Med, Birmingham B18 7QH, W Midlands, England
[2] Univ Hosp Virgen Arrixaca, Dept Cardiol, Murcia, Spain
关键词
anticoagulation; bleeding; chronic kidney disease; mortality; percutaneous coronary intervention; ACUTE-MYOCARDIAL-INFARCTION; ANTIPLATELET THERAPY USE; ATRIAL-FIBRILLATION; CLINICAL-OUTCOMES; WARFARIN THERAPY; SERUM CREATININE; RENAL-FUNCTION; INTERVENTION; TRIAL; RISK;
D O I
10.1378/chest.08-1425
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Patients with indications for oral anticoagulation (OAC) undergoing percutaneous coronary artery stenting (PCI-S) represent a high-risk population for major bleeding complications. Chronic kidney disease (CKD) is also associated with poor outcome after PCI-S. Limited data are available regarding the impact of CKD on the frequency, of major bleeding and mortality in this population. Methods: We investigated the influence of CKD on major bleeding and all-cause mortality in patients with indication for OAC who undergo PCI-S. Patients were grouped according to calculated creatinine clearance (CrCl): CrCl > 60 mL/min, (n = 98) and CrCl <= 60 mL/min, (n = 68). Major bleeding and major adverse vascular events (all-cause mortality, myocardial infarction, repeat revascularization, stent thrombosis, or stroke) were collected during follow-up. Results: We analyzed 166 consecutive patients with indication(s) for OAC (77% men; mean age, 71 years; range, 66 to 76 years) after undergoing PCI-S. CKD was associated with higher risk for major bleeding (hazard ratio [HR], 3.44; 95% confidence interval [CI], 1.50 to 7.93; p = 0.004) and all-cause mortality (HR, 3.50; 95% CI, 1.53 to 7.99; p = 0.003). In multivariate analyses, age > 75 years (HR, 2.75; 95% CI, 1.15 to 6.56; p = 0.023), CKD (HR, 2.59; 95% CI, 1.00 to 6.95; p = 0.049), anemia (HR, 2.36; 95% CI, 1.00 to 5.54; p = 0.049), and triple antithrombotic therapy (HR, 3.29; 95% CI, 1.23 to 8.84; p = 0.018) were independent predictors for major bleeding, whereas age > 75 years (HR, 2.38; 95% CI, 1.03 to 5.59; p = 0.046) and CKD (HR, 2.44; 95% CI, 1.03 to 5.82; p = 0.044) were predictors for all-cause mortality. Conclusion: In this high-risk population, CKD is independently associated with increased major bleeding and all-cause mortality following PCI-S.
引用
收藏
页码:983 / 990
页数:8
相关论文
共 26 条
  • [1] Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting
    Azar, RR
    Prpic, R
    Ho, KKL
    Kiernan, FJ
    Shubrooks, SJ
    Baim, DS
    Popma, JJ
    Kuntz, RE
    Cohen, DJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (05) : 485 - 489
  • [2] Bazzino O, 1998, NEW ENGL J MED, V338, P1488
  • [3] The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial
    Berger, PB
    Best, PJM
    Topol, EJ
    White, J
    DiBattiste, PM
    Chan, AW
    Kristensen, SD
    Herrmann, HC
    Moliterno, DJ
    [J]. AMERICAN HEART JOURNAL, 2005, 149 (05) : 869 - 875
  • [4] The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions
    Best, PJM
    Lennon, R
    Ting, HH
    Bell, MR
    Rihal, CS
    Holmes, DR
    Berger, PB
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (07) : 1113 - 1119
  • [5] Impact of mild or moderate chronic kidney disease on the frequency of restenosis - Results from the PRESTO trial
    Best, PJM
    Berger, PB
    Davis, BR
    Grines, CL
    Sadeghi, HM
    Williams, BA
    Willerson, JT
    Granett, JR
    Holmes, DR
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (09) : 1786 - 1791
  • [6] Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy
    DeEugenio, Deborah
    Kolman, Louis
    DeCaro, Matthew
    Andrel, Jocelyn
    Chervoneva, Inna
    Duong, Phu
    Lam, Linh
    McGowan, Christopher
    Lee, Grace
    DeCaro, Mark
    Ruggiero, Nicholas
    Singhal, Shalabh
    Greenspon, Arnold
    [J]. PHARMACOTHERAPY, 2007, 27 (05): : 691 - 696
  • [7] Guide to anticoagulant therapy: Heparin a statement for healthcare professionals from the American Heart Association
    Hirsh, J
    Anand, SS
    Halperin, JL
    Fuster, V
    [J]. CIRCULATION, 2001, 103 (24) : 2994 - 3018
  • [8] Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting
    Karjalainen, Pasi P.
    Porela, Pekka
    Ylitalo, Antti
    Vikman, Saila
    Nyman, Kai
    Vaittinen, Mari-Anne
    Airaksinen, Tuukka J.
    Niemela, Matti
    Vahlberg, Tero
    Airaksinen, K. E. Juhani
    [J]. EUROPEAN HEART JOURNAL, 2007, 28 (06) : 726 - 732
  • [9] Khurram Zakaria, 2006, J Invasive Cardiol, V18, P162
  • [10] Correlates of bleeding events among moderate-to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide - Observations from the PROTECT-TIMI-30 Trial
    Kirtane, Ajay J.
    Piazza, Gregory
    Murphy, Sabina A.
    Budiu, Damela
    Morrow, David A.
    Cohen, David J.
    Peterson, Eric
    Lakkis, Nasser
    Herrmann, Howard C.
    Palabrica, Theresa M.
    Gibson, C. Michael
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (12) : 2374 - 2379